Quarterly report pursuant to Section 13 or 15(d)

Organization and Business

v2.4.0.6
Organization and Business
6 Months Ended
Jun. 30, 2012
Basis of Presentation/Organization and Business [Abstract]  
Organization and Business

2.    Organization and Business

Business Summary

The Company is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, the Company has developed and licensed patented and patent pending technologies which are used in its portfolio of products. This product portfolio includes Avance® Nerve Graft, a commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed) of 5mm to 70mm in length, Avance® Nerve Graft is sterilized and processed using a patented cleaning process that preserves the inherent and relevent structural characteristics of the tissue allowing regenerating axons to grow through the scaffold to the motor or sensory organ.

AxoGen’s portfolio also includes AxoGuard ® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard ® Nerve Protector, a bioscaffold used to reinforce a cooptation site, wrap a partially severed nerve or isolate and protect nerve tissue.